US Patent 8,778,960: Aripiprazole Patent Scope, Expiration, Orange Book Status, and Generic Risk
US Patent 8,778,960 protects a narrow method of using aripiprazole, or a pharmaceutically acceptable salt, to reduce weight gain caused by olanzapine. It does not claim aripiprazole itself, olanzapine itself, a fixed-dose combination, or a general obesity treatment. The patent is a method-of-use patent with projected exclusivity extending into 2028, but its commercial blocking power is limited because the claimed use is not a principal FDA-approved indication for aripiprazole.
What does US Patent 8,778,960 cover?
US 8,778,960 covers administering aripiprazole to a patient receiving olanzapine or another atypical antipsychotic treatment, where the objective is to reduce antipsychotic-induced weight gain.
The patent's operative limitation is the use of the claimed compound in a patient treated with olanzapine. The formula in the claims corresponds to aripiprazole, also known as OPC-14597 and marketed by Otsuka Pharmaceutical under the brand Abilify.
| Patent element |
Scope |
| Patent |
US 8,778,960 B2 |
| Patent type |
Method of treatment |
| Active compound |
Aripiprazole or pharmaceutically acceptable salt |
| Primary antipsychotic |
Olanzapine |
| Therapeutic objective |
Reducing antipsychotic-induced weight gain |
| Dose limitation |
About 3 to about 30 mg/day |
| Route limitation |
Oral administration in dependent claim 3 |
| Patient selection |
Approximately 5% weight gain within one week or within one year of atypical antipsychotic treatment |
| Patent holder |
Otsuka-related aripiprazole patent estate |
| Core commercial product |
Abilify, aripiprazole |
The claims are narrower than a claim to adjunctive aripiprazole treatment generally. A practicing party would need to satisfy the elements of the asserted claim, including the purpose of reducing weight gain and, for the dependent claims, the dose, route, or patient weight-gain criteria.
How do the claims of US 8,778,960 differ?
Claim 1: Core method claim
Claim 1 requires:
- A patient in need of treatment.
- Administration of aripiprazole or a pharmaceutically acceptable salt.
- An effective amount.
- A method directed to reducing antipsychotic-induced weight gain.
- Olanzapine as the antipsychotic causing or associated with the weight gain.
Claim 1 is the principal infringement risk. It does not require a particular dose, route, weight-gain threshold, treatment duration, or formulation.
The claim is not limited to patients who have already gained a specified amount of weight. A product label or clinical protocol that expressly directs aripiprazole use to prevent or reduce olanzapine-associated weight gain would present a stronger method-of-use risk than a label directed only to schizophrenia, bipolar disorder, major depressive disorder adjunctive therapy, autism-associated irritability, or Tourette's disorder.
Claim 2: Dose limitation
Claim 2 limits the daily aripiprazole dose to approximately 3 to 30 mg/day. The phrase "about" creates a range of ordinary pharmaceutical tolerance rather than a rigid numerical boundary.
The claim is commercially relevant because marketed aripiprazole tablets include 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. The 3 mg lower boundary does not correspond directly to every marketed strength, but common clinical dosing within the claimed range would fall within the claim if the other limitations are met.
Claim 3: Oral administration
Claim 3 requires the daily dose to be administered orally. It narrows claim 2 and reaches conventional aripiprazole tablets, orally disintegrating tablets, and oral liquid formulations if the prescribed daily amount falls within the claimed range.
The claim does not expressly require a tablet, capsule, solution, or orally disintegrating dosage form. It is a route-of-administration limitation, not a formulation claim.
Claim 4: Rapid weight-gain population
Claim 4 covers patients who gained approximately 5% of body weight within one week of starting atypical antipsychotic therapy.
This limitation creates a patient-selection requirement. A plaintiff would need evidence that the patient met the stated weight-gain criterion and that the accused treatment was directed to reducing the resulting weight gain. The use of "about 5%" raises claim-construction issues concerning measurement precision, baseline weight, and the permissible deviation from 5%.
Claim 5: Longer-term weight-gain population
Claim 5 covers patients who gained approximately 5% of body weight within one year of atypical antipsychotic treatment.
Claim 5 depends directly on claim 1 rather than claim 4. It therefore provides an alternative patient-selection pathway. The patient need not necessarily satisfy the one-week threshold in claim 4 if the one-year criterion in claim 5 is met.
What does US 8,778,960 not cover?
The patent does not claim the following subject matter on its face:
- Aripiprazole as a chemical compound.
- Aripiprazole tablets as a composition.
- Olanzapine as a chemical compound.
- Olanzapine tablets or orally disintegrating tablets.
- A fixed-dose aripiprazole-olanzapine combination.
- Treatment of weight gain caused by every antipsychotic.
- Treatment of weight gain without aripiprazole.
- General obesity treatment.
- A sustained-release aripiprazole formulation.
- A manufacturing process for aripiprazole.
- A formulation containing a particular excipient.
- A method that does not involve olanzapine where claim 1's olanzapine limitation is not otherwise satisfied.
The patent therefore has limited reach against generic olanzapine manufacturers. A generic olanzapine product does not practice the claimed method merely because patients taking it may gain weight. The core claim requires administration of aripiprazole for the specified therapeutic purpose.
When does US Patent 8,778,960 expire?
The patent has a projected statutory term extending into 2028 based on the effective priority and filing history associated with the patent family. The commercially relevant estimate is December 2028, subject to the patent's official term calculation, patent-term adjustment, and any terminal-disclaimer effects recorded by the USPTO.
| Exclusivity component |
Relevance |
| US patent grant |
September 2, 2014 |
| Projected patent term |
Into December 2028 |
| Patent type |
Method-of-use |
| Patent-term extension |
No established basis for a separate extension directed to this weight-gain indication |
| Small-molecule regulatory exclusivity |
Not created by this patent |
| Pediatric exclusivity |
Must be evaluated separately from the patent term |
The patent's remaining value depends less on the chemical exclusivity of aripiprazole, which expired earlier, and more on whether a generic applicant's labeling, marketing, prescribing materials, or post-approval conduct causes the generic product to be used for the patented method.
What is the Orange Book status of US 8,778,960?
The patent should be evaluated separately from the Orange Book patents that protected the aripiprazole active ingredient, Abilify formulations, or FDA-approved aripiprazole uses.
The weight-gain method claimed by US 8,778,960 is not a standard labeled indication in the FDA-approved Abilify prescribing information. The approved labeling covers schizophrenia, bipolar I disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and Tourette's disorder, subject to product-specific labeling [2].
Because Orange Book method-of-use listing generally depends on a patent claiming an approved method of using the drug, a weight-gain patent directed to an unapproved or off-label use has weaker Orange Book relevance than a patent covering an indication included in the approved labeling [3].
| Orange Book issue |
Assessment |
| Active ingredient protection |
Expired for original aripiprazole exclusivity |
| Weight-gain method listing |
Limited relevance unless tied to an approved labeling indication |
| Formulation listing |
Not established by the claims provided |
| Use code |
Would need to identify an approved use corresponding to the patented method |
| Generic labeling risk |
More likely managed through a section viii carve-out or non-infringing label strategy |
An Orange Book listing, if present at any relevant time, would not expand the patent's claim scope. It would affect ANDA notice, certification, and approval timing.
Which companies challenged the aripiprazole patent estate?
The principal generic challenges to aripiprazole involved companies seeking approval for generic Abilify after the expiry of Otsuka's core compound and product protection. Publicly reported Abilify patent litigation included proceedings involving Teva, Sandoz, and other ANDA applicants.
The main patent disputes focused on the broader aripiprazole estate, including patents directed to the compound, dosage forms, and approved uses. A generic applicant's Paragraph IV certification against an Orange Book-listed patent can trigger Hatch-Waxman litigation under 21 U.S.C. § 355(j), but a Paragraph IV challenge to a different aripiprazole patent does not automatically establish that US 8,778,960 was the asserted patent in every Abilify case.
The commercial distinction is important:
- Generic aripiprazole approval can proceed for non-infringing indications.
- A generic applicant can seek approval with a carved-out label for a patented method.
- A method patent may remain enforceable even after the branded product's compound patent expires.
- The patent does not necessarily prevent sale of generic aripiprazole for unrelated approved indications.
Are there Paragraph IV risks under US 8,778,960?
A Paragraph IV risk exists only if the patent is listed for the relevant product and the ANDA applicant certifies that the patent is invalid, unenforceable, or not infringed.
For this patent, the more likely generic strategy is a section viii statement or labeling carve-out rather than a direct attack on the weight-gain method. A generic aripiprazole applicant could omit an indication or use instruction that encourages treatment of olanzapine-induced weight gain, provided the FDA accepts the proposed labeling and the remaining label does not retain the patented method.
The principal litigation risks are:
- Induced infringement. Marketing materials, patient materials, sales training, or other communications could encourage the patented use even if the FDA label omits it.
- Label overlap. A broad instruction to use aripiprazole adjunctively with antipsychotics could be argued to encompass the claimed olanzapine use, depending on the exact label language.
- Clinical-trial evidence. Studies directed to prevention or treatment of olanzapine-related weight gain could support an inducement theory if linked to commercial launch.
- Patient-selection evidence. Claims 4 and 5 require proof of the specified weight-gain profile, which may limit enforcement against routine use.
What formulation patents are relevant?
US 8,778,960 is not a formulation patent. It does not claim particle size, excipient ratios, dissolution characteristics, tablet hardness, orally disintegrating technology, depot delivery, or a controlled-release matrix.
Relevant adjacent patent categories include:
| Patent category |
Business relevance |
| Aripiprazole compound patents |
Historical core exclusivity; generally expired |
| Oral tablet patents |
May affect generic formulation timing |
| Orally disintegrating tablet patents |
Potentially relevant to Abilify Discmelt-type products |
| Long-acting injectable patents |
Relevant to Abilify Maintena and later injectable products |
| Method-of-use patents |
Can restrict specific prescribing purposes |
| Manufacturing patents |
May create process-substitution or freedom-to-operate issues |
A company developing a generic or follow-on aripiprazole product must conduct a separate family-level search for formulation, polymorph, process, injectable, and device patents. None of those rights can be inferred from the claims of US 8,778,960.
How strong is the patent estate for this indication?
The patent is technically narrow but potentially enforceable where prescribing evidence is direct.
| Strength factor |
Assessment |
| Claim clarity |
Moderate; compound and antipsychotic are identifiable |
| Chemical coverage |
None beyond the use of aripiprazole |
| Formulation coverage |
None |
| Patient selection |
Narrows claims 4 and 5 but may create proof burdens |
| Dose coverage |
Broad within ordinary oral aripiprazole dosing |
| Label-based enforcement |
Limited if weight-gain use is omitted from generic labeling |
| Off-label use enforcement |
Fact-intensive |
| Biosimilar relevance |
None; aripiprazole is a small molecule |
| Generic substitution risk |
High for unrelated indications; lower for deliberate patented use |
Claim 1 is stronger than claims 4 and 5 because it avoids the numerical weight-gain thresholds. Claims 4 and 5 may be more vulnerable to factual disputes involving baseline weight, measurement timing, causation, and the meaning of "about 5%."
The patent's commercial strength is therefore asymmetric. It is weak as a barrier to generic aripiprazole across the market but stronger against a branded or generic product intentionally positioned as an adjunct to olanzapine for weight-gain management.
What litigation and settlement issues affect the patent?
A settlement involving other Otsuka aripiprazole patents does not automatically resolve US 8,778,960. Each patent must be checked for:
- Whether it was listed in the Orange Book.
- Whether an ANDA applicant certified against it.
- Whether it was asserted in the resulting litigation.
- Whether the patent was dismissed, invalidated, or held unenforceable.
- Whether a settlement included a launch date or license.
- Whether the settlement preserved a carved-out label.
Generic Abilify settlements often had greater commercial importance for the compound, formulation, or approved-use patents than for a narrow off-label weight-gain method. The absence of a direct assertion against a particular ANDA applicant would materially reduce immediate launch risk but would not eliminate theoretical infringement exposure.
How does US 8,778,960 compare with competing weight-gain strategies?
| Strategy |
Patent position |
Regulatory position |
| Aripiprazole adjunctive treatment |
Covered by US 8,778,960 for olanzapine-associated weight gain |
Weight-gain use is generally off-label |
| Metformin |
Separate clinical and patent landscape |
Not specifically approved for antipsychotic-induced weight gain |
| Lifestyle intervention |
No comparable drug patent barrier |
Standard supportive management |
| Switching antipsychotics |
Depends on the replacement drug's estate |
May be within approved psychiatric treatment |
| GLP-1 receptor agonists |
Separate molecule and indication patents |
Weight-loss indications may be approved for specific products |
| Topiramate or other adjunctive agents |
Separate patents and clinical evidence |
Use depends on approved indication and prescribing practice |
US 8,778,960 has no biosimilar exposure because aripiprazole is a conventional small-molecule drug. The relevant competitive threat is generic substitution and off-label prescribing, not biosimilar interchangeability.
What generic launch scenarios exist?
Scenario 1: Generic aripiprazole with a carved-out label
This is the lowest-risk route for a generic applicant. The label omits the patented weight-gain use, while retaining non-infringing approved indications. Commercial launch can proceed subject to the remaining patent and regulatory barriers.
Scenario 2: Generic label includes broad adjunctive use
A broad label may create greater risk if it expressly identifies olanzapine or weight-gain reduction. The risk increases where promotional materials or clinical support documents reinforce that use.
Scenario 3: Authorized generic or license
An Otsuka license or authorized-generic arrangement could reduce litigation exposure, but the business terms would need to address the relevant patent families rather than US 8,778,960 in isolation.
Scenario 4: Post-expiration launch
After the patent term ends, the method claim no longer creates ordinary infringement exposure for future conduct, subject to any validly extended term or separate patent rights.
Does US 8,778,960 create manufacturing or geographic barriers?
The patent creates no manufacturing-process barrier because the claims do not require a particular process, polymorph, particle size, excipient, or dosage form.
Its geographic scope is limited to the United States. Parallel patent rights may exist in other jurisdictions, but foreign family members require separate review of national-phase prosecution, granted claims, term adjustments, oppositions, and lapse records.
For a global launch, the relevant workstreams are:
- US method-of-use and Orange Book review.
- European and UK family-member status.
- Canada, Japan, South Korea, Australia, and other major-market equivalents.
- Local rules governing skinny labels and induced infringement.
- Product-specific formulation and injectable patents.
- Regulatory labeling differences for aripiprazole and olanzapine.
Key Takeaways
- US 8,778,960 is a narrow method-of-use patent involving aripiprazole and olanzapine-associated weight gain.
- Claim 1 is the commercially important claim.
- Claims 2 and 3 add a 3 to 30 mg/day dose range and oral administration.
- Claims 4 and 5 add alternative patient-selection thresholds based on approximately 5% weight gain.
- The patent does not claim aripiprazole, olanzapine, a fixed-dose combination, or a formulation.
- The projected patent term extends into December 2028.
- The patent is more relevant to inducement and labeling strategy than to generic aripiprazole composition-of-matter entry.
- Biosimilar risk is not applicable.
- Generic applicants can potentially avoid the claimed method through a section viii or skinny-label strategy.
- Formulation, injectable, process, and device patents must be analyzed separately.
- Orange Book significance depends on whether the patented method corresponds to an FDA-approved labeled use.
FAQs
Is aripiprazole approved by the FDA to treat olanzapine-induced weight gain?
No. The FDA-approved aripiprazole labeling does not establish reduction of olanzapine-induced weight gain as a principal approved indication [2].
Can a generic aripiprazole company sell product while US 8,778,960 remains in force?
Potentially. A generic can seek approval for non-infringing indications and omit the patented weight-gain use from its labeling, subject to FDA acceptance and the status of other patents.
Does US 8,778,960 cover metformin treatment of antipsychotic weight gain?
No. The claims require aripiprazole or its pharmaceutically acceptable salt. They do not cover metformin.
Does the patent cover aripiprazole long-acting injection?
The claims provided do not require or exclude a particular formulation or route in claim 1. Claim 3 is limited to oral administration, but claim 1 is not. Separate injectable-product patents and claim-construction issues must be considered.
Can the patent be infringed by a physician prescribing aripiprazole off label?
Potential liability would depend on the applicable US infringement theory and evidence of the claimed method, including the olanzapine-associated weight-gain purpose. In practice, enforcement risk is more commonly directed toward manufacturers, marketers, or parties alleged to induce the patented use.
References
- United States Patent and Trademark Office. (2014). US Patent No. 8,778,960 B2: Use of aripiprazole for treating antipsychotic-induced weight gain.
- U.S. Food and Drug Administration. (2023). Abilify (aripiprazole) prescribing information. Otsuka America Pharmaceutical, Inc.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Applications covered by patent information submitted to FDA.
- 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.
- 35 U.S.C. §§ 154, 156. Patent term and patent-term extension provisions.
